ORGS has 2 divisions: 1) CDMO is a NASDAQ listed contract mfr/developer of cell based therapies 2) R & D program focused on converting liver cells into insulin producing cells
CDMO is growing at a rate corresponding to the Cell Therapies growth rates. CDMO grew 58% in 2017.
CDMO competes with WXXWY & LZAGY
CRSP is a significant client of CDMO, along with Servier & Zelluna.
ORGS intends to file an IND for Autologous Insulin Cell Production technology this year.
Potential catalysts include:
* Sell-side coverage. ORGS uplisted from OTC and presently has minimal institutional support * Positive news associated with a major client. CRSP can be very news driven * Entering into a agreement with a new mfrng/development client
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.